243 related articles for article (PubMed ID: 31475103)
21. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
22. CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite).
Erzen C; Eryilmaz M; Kalyoncu F; Bilir N; Sahin A; Baris YI
J Comput Assist Tomogr; 1991; 15(2):256-60. PubMed ID: 1848247
[TBL] [Abstract][Full Text] [Related]
23. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
Kokturk N; Firat P; Akay H; Kadilar C; Ozturk C; Zorlu F; Gungen Y; Emri S
Lung Cancer; 2005 Nov; 50(2):189-98. PubMed ID: 16043260
[TBL] [Abstract][Full Text] [Related]
25. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous Use of Endobronchial and Endoscopic Ultrasound Guidance as Primary Tools in the Diagnosis of Malignant Pleural Mesothelioma.
Mankidy B; Sparkman J; Boddu S; Huang Q; Sharma M
Cureus; 2022 Dec; 14(12):e32110. PubMed ID: 36601180
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
28. An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
Dragonieri S; van der Schee MP; Massaro T; Schiavulli N; Brinkman P; Pinca A; Carratú P; Spanevello A; Resta O; Musti M; Sterk PJ
Lung Cancer; 2012 Mar; 75(3):326-31. PubMed ID: 21924516
[TBL] [Abstract][Full Text] [Related]
29. Soluble markers for diagnosis of malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Bruno R; Foddis R
Biomark Med; 2011 Apr; 5(2):261-73. PubMed ID: 21473730
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of malignant pleural mesothelioma.
Jaurand MC; Fleury-Feith J
Respirology; 2005 Jan; 10(1):2-8. PubMed ID: 15691231
[TBL] [Abstract][Full Text] [Related]
31. [Current problems in the diagnosis of malignant pleural mesothelioma].
Hosokawa Y; Matsuge S; Hayashi K; Tao Y; Nakno R; Kemmochi Y; Ishimine A; Murakami Y; Kano S
Kyobu Geka; 2007 Jan; 60(1):14-8. PubMed ID: 17249532
[TBL] [Abstract][Full Text] [Related]
32. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
Bruno R; Alì G; Fontanini G
J Thorac Dis; 2018 Jan; 10(Suppl 2):S342-S352. PubMed ID: 29507804
[TBL] [Abstract][Full Text] [Related]
33. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
Scherpereel A;
Respir Med; 2007 Jun; 101(6):1265-76. PubMed ID: 17137779
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.
Lin RC; Kirschner MB; Cheng YY; van Zandwijk N; Reid G
Genom Data; 2016 Sep; 9():44-9. PubMed ID: 27408810
[TBL] [Abstract][Full Text] [Related]
35. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
Maeda R; Tabata C; Tabata R; Eguchi R; Fujimori Y; Nakano T
Antioxid Redox Signal; 2011 Aug; 15(3):685-9. PubMed ID: 21375472
[TBL] [Abstract][Full Text] [Related]
36. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
Nicolini F; Bocchini M; Bronte G; Delmonte A; Guidoboni M; Crinò L; Mazza M
Front Oncol; 2019; 9():1519. PubMed ID: 32039010
[TBL] [Abstract][Full Text] [Related]
37. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey.
Senyiğit A; Babayiğit C; Gökirmak M; Topçu F; Asan E; Coşkunsel M; Işik R; Ertem M
Respiration; 2000; 67(6):610-4. PubMed ID: 11124642
[TBL] [Abstract][Full Text] [Related]
38. Malignant mesothelioma: experience at the Singapore General Hospital.
Chan K; Tan KL; Lee HS; Eng P
Ann Acad Med Singap; 2003 May; 32(3):388-91. PubMed ID: 12854383
[TBL] [Abstract][Full Text] [Related]
39. Clinical diagnosis of malignant pleural mesothelioma.
Bianco A; Valente T; De Rimini ML; Sica G; Fiorelli A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S253-S261. PubMed ID: 29507793
[TBL] [Abstract][Full Text] [Related]
40. [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Ciuccarelli M; Valentino M; Governa M; Santarelli L
G Ital Med Lav Ergon; 2007; 29(3 Suppl):335-8. PubMed ID: 18409713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
